EGFR and non-small cell lung carcinoma: In a biomarker analysis of the NEJ026 phase III study comparing erlotinib plus bevacizumab combination therapy with erlotinib monotherapy in EGFR‐mutated NSCLC,17 patients without ctDNA EGFRm at baseline had longer PFS compared to patients with ctDNA EGFRm.